Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance

Julie Strizki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hiroshi Mohri(Aaron Diamond AIDS Research Center), Beth Hutchins(Merck & Co., Inc., Rahway, NJ, USA (United States)), Philip M. McKenna(University of Pennsylvania), Keith C. Kinek(Merck & Co., Inc., Rahway, NJ, USA (United States)), Manoj S. Nair(Aaron Diamond AIDS Research Center), John A. Howe(Merck & Co., Inc., Rahway, NJ, USA (United States)), John M. Gaspar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shih Lin Goh(Merck & Co., Inc., Rahway, NJ, USA (United States))
Antimicrobial Agents and Chemotherapy
December 4, 2023
10.1128/aac.00953-23
Cited by 33

Related Papers

Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
|Science|2004|1.8k
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
|Nature|2020|1.6k
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
|Nature|2021|1.4k
Antibiotic Susceptibility Profiles of <i>Escherichia coli</i> Strains Lacking Multidrug Efflux Pump Genes
|Antimicrobial Agents and Chemotherapy|2001|502
The Macaque Gut Microbiome in Health, Lentiviral Infection, and Chronic Enterocolitis
|PLoS Pathogens|2008|438